Novel targeted deregulation of c-Myc cooperates with Bcl-X(L) to cause plasma cell neoplasms in mice. - Wikidata - awgldk - TriplyDB

Novel targeted deregulation of c-Myc cooperates with Bcl-X(L) to cause plasma cell neoplasms in mice.

Novel targeted deregulation of c-Myc cooperates with Bcl-X(L) to cause plasma cell neoplasms in mice.

http://www.wikidata.org/entity/Q34380431

about

The diabetes-linked transcription factor PAX4 promotes {beta}-cell proliferation and survival in rat and human islets Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma A novel mouse model for multiple myeloma (MOPC315.BM) that allows noninvasive spatiotemporal detection of osteolytic disease The IgH 3' regulatory region and c-myc-induced B-cell lymphomagenesis Osteolytica: An automated image analysis software package that rapidly measures cancer-induced osteolytic lesions in in vivo models with greater reproducibility compared to other commonly used methods Bortezomib resistance can be reversed by induced expression of plasma cell maturation markers in a mouse in vitro model of multiple myeloma KSHV Latency Locus Cooperates with Myc to Drive Lymphoma in Mice Deregulation of c-Myc Confers distinct survival requirements for memory B cells, plasma cells, and their progenitors Gene expression profiling reveals different pathways related to Abl and other genes that cooperate with c-Myc in a model of plasma cell neoplasia.IL-6 and MYC collaborate in plasma cell tumor formation in mice.Tracking human multiple myeloma xenografts in NOD-Rag-1/IL-2 receptor gamma chain-null mice with the novel biomarker AKAP-4 Plasmacytomagenesis in Eμ-v-abl transgenic mice is accelerated when apoptosis is restrained.B-cell activating factor and v-Myc myelocytomatosis viral oncogene homolog (c-Myc) influence progression of chronic lymphocytic leukemia.Kaposi sarcoma-associated herpesvirus-encoded viral FLICE inhibitory protein (vFLIP) K13 cooperates with Myc to promote lymphoma in mice.CDDO-Imidazolide inhibits growth and survival of c-Myc-induced mouse B cell and plasma cell neoplasms.GP130 activation induces myeloma and collaborates with MYC.A therapeutic role for targeting c-Myc/Hif-1-dependent signaling pathways.The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis.Targeting signalling pathways for the treatment of multiple myeloma.Anaplastic plasmacytomas: relationships to normal memory B cells and plasma cell neoplasms of immunodeficient and autoimmune mice.AID-deficient Bcl-xL transgenic mice develop delayed atypical plasma cell tumors with unusual Ig/Myc chromosomal rearrangements.Regulation of AID expression in the immune response Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies.Growth factors and antiapoptotic signaling pathways in multiple myeloma.Myeloid-derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow.Bone marrow PMN-MDSCs and neutrophils are functionally similar in protection of multiple myeloma from chemotherapy BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic mice In a model of immunoglobulin heavy-chain (IGH)/MYC translocation, the Igh 3' regulatory region induces MYC expression at the immature stage of B cell development.Restricting activation-induced cytidine deaminase tumorigenic activity in B lymphocytes.A novel rapid-onset high-penetrance plasmacytoma mouse model driven by deregulation of cMYC cooperating with KRAS12V in BALB/c mice.c-Myc induction of programmed cell death may contribute to carcinogenesis: a perspective inspired by several concepts of chemical carcinogenesis.The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy.Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases New frontiers in promoting tumour cell death: targeting apoptosis, necroptosis and autophagy.Mouse models as a translational platform for the development of new therapeutic agents in multiple myeloma.The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma.Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model.Generation of precursor, immature, and mature murine B1-cell lines from c-myc/bcl-xL-overexpressing pre-BI cells.Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib Targeted overexpression of an activated N-ras gene results in B-cell and plasma cell lymphoproliferation and cooperates with c-myc to induce fatal B-cell neoplasia.

P2860

Q24675974-CBBC3874-F111-4F50-8EDE-98259607D7B5 Q27027729-6A18BB63-A608-41C6-8720-C84A3AB779B1 Q27329429-B2056550-C4BA-485C-87E4-84CB5DBC9BFE Q28075599-FC040584-09D2-4618-9C52-F45501429215 Q28364664-25999EA9-CFAD-466E-A59C-481F2942C1CD Q28534703-B628EF1B-796F-4DCA-A2F7-83F9EC301D23 Q28547671-812CB8B3-E4AD-46C9-8944-D43C4EF435B0 Q30436741-BF7813BB-C84B-4A7D-9F3D-8318ED23417B Q30444311-D4077AAA-38E9-4211-9611-F9482DCAB968 Q33706389-C6A6BC94-801C-47D5-B823-7E87948DBD2E Q34020937-E03EA002-B8C7-4F02-B789-DF2E1FB66ADB Q34047859-AE607A57-303C-4E65-B27C-F669ACAACCB7 Q34279007-64943658-10DC-4374-924E-F6654E055357 Q34616590-2B5E41DE-C768-4839-94BE-17AD68688A19 Q35005660-8FB78F89-C3D4-48C2-AC5C-7728A619F6EC Q35145350-A8186E13-8089-4F80-83B3-D8DC8E6E3550 Q35163974-71593B1B-1F53-4134-8939-694E9AC08DEE Q35830099-AC4BC295-E107-427B-8357-30DADFC2C80A Q36150866-DC6E14C8-1E7A-4F26-80AF-78C503B8D403 Q36154339-70F7DAC4-2D51-48A8-B76E-6A16D6EEDE2C Q36229165-A6C4560B-BE0D-45CA-971B-0353CE81B576 Q36229307-143A2866-0174-4A2D-A0DD-70C113C1DF2C Q36238764-452A69DE-E894-4F88-A384-1885ED73BD05 Q36292888-AA3EABF4-7CA3-4DE1-B4AB-74C3455D2235 Q36718300-E4C4243C-ADBD-48E8-9880-3D08112352C2 Q37035522-5CA7C5EF-8673-4187-B00D-601123603933 Q37197900-C58F92E1-0E6D-44CC-8D03-79EC751436E9 Q37342819-1497FC5D-FB88-419B-A815-97244506DFE8 Q37419452-46525148-4475-4D9B-A1AD-CB8D5FEEEA58 Q37431980-34E0CF0A-F46E-46A8-9571-69059A1E27E2 Q37833424-83D75397-445A-4A79-92E9-B875C39C197A Q37854419-C55A6F06-12C0-41B3-B0DC-22B70292F2C1 Q37921609-15CB3DEA-EF91-4E16-8CCD-BF38B1D9ACCE Q37981834-41A99E23-FC77-414A-A5FC-E6C0A7CE7E33 Q38016511-6EB40616-E253-4930-8B4C-1E0F4CF391DE Q38400460-52FAED4C-DB33-4660-8D47-35EEA3EC1227 Q39174431-FA6C14DB-80BB-4DB6-8582-583093AC1154 Q40293911-1A98D4E5-7A01-42FC-BD42-D56D9CAB076B Q40593240-49259D9C-0D7A-4C75-B879-DC4FC7A200EB Q41121076-50D793F9-B55B-4944-A15B-93356E309036

P2860

Novel targeted deregulation of c-Myc cooperates with Bcl-X(L) to cause plasma cell neoplasms in mice.

http://www.wikidata.org/entity/Q34380431

description

2004 nî lūn-bûn

@nan

2004 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Novel targeted deregulation of c-Myc cooperates with Bcl-X

@nl

Novel targeted deregulation of ...... plasma cell neoplasms in mice.

@ast

Novel targeted deregulation of ...... plasma cell neoplasms in mice.

@en

type

label

Novel targeted deregulation of c-Myc cooperates with Bcl-X

@nl

Novel targeted deregulation of ...... plasma cell neoplasms in mice.

@ast

Novel targeted deregulation of ...... plasma cell neoplasms in mice.

@en

prefLabel

Novel targeted deregulation of c-Myc cooperates with Bcl-X

@nl

Novel targeted deregulation of ...... plasma cell neoplasms in mice.

@ast

Novel targeted deregulation of ...... plasma cell neoplasms in mice.

@en

P1433

Q34380431-3813203A-5DE5-4449-9E67-05E8AAB1BC09

P1476

Q34380431-C28EC614-B106-48E2-BDBE-0F9D299FB667

P2093

Q34380431-1273F870-4D61-4406-A82D-0739A45CA99B

Q34380431-701E97F9-F5C6-4D7A-BDDA-6BF4EFD91AA0

Q34380431-B33DA148-D568-4ACA-813C-4BBA6C20798A

Q34380431-BB5A3C33-DCBE-47C3-A858-FDAE88C96966

Q34380431-C35269C6-8FAB-450C-A841-A55424918F64

Q34380431-D7183F98-08E1-4678-B6FE-0B6198ECC2DA

Q34380431-D9FFE374-428A-466E-AC8C-85C719AE4F31

P2860

Q34380431-01E7FD60-0F1F-41FE-9179-0DF60A19F784

Q34380431-02405716-A33C-4A0C-8E63-D50E7CDAA1EE

Q34380431-033EF969-9FBA-465E-8497-9ABD03E3D5C5

Q34380431-0631E98D-EE99-4375-BA22-440D8B7B002A

Q34380431-0760C81F-5E52-489F-94E9-8A954BAA6223

Q34380431-087D0943-7F4E-4A91-90D8-621851A3A029

Q34380431-0A65D683-987E-42A5-B7DF-94062CDC0687

Q34380431-0A675B12-1176-4EB9-8EC3-C4B8EB08A458

Q34380431-13C12FB0-2C26-4BD8-BA83-580166A32A42

Q34380431-14EE8389-6802-4519-8015-89914574C965

P304

Q34380431-04CB4E95-9D64-4FF8-AC44-6258274BD2F2

P31

Q34380431-FB171C72-E7F2-4537-8D49-48231F1E971F

P356

Q34380431-5690B3B1-55DE-499A-AC94-95A23E0E395C

P407

Q34380431-85B11ABD-1D64-4118-AC48-599E6CA14611

P433

Q34380431-1DF7F91F-DF83-4500-82DD-584DE656E642

P478

Q34380431-B66D42CA-8CE9-4A92-8DD5-DF215CB50416

P50

Q34380431-47B2FEFE-0528-4673-8B0B-48DFFF5CE03E

P577

Q34380431-1CD566E4-3C69-4017-8986-B6AB3B81BE5F

P698

Q34380431-AAC6B822-4D36-4D3F-85DB-29D70E4FC8C9

P932

Q34380431-BFE730A6-D6FB-4751-8E9A-26E4217A8443

P356

P1433

Journal of Clinical Investigation

P1476

Novel targeted deregulation of ...... plasma cell neoplasms in mice.

@en

P2093

Brian Van Ness

http://www.w3.org/2001/XMLSchema#string

Joong Su Kim

http://www.w3.org/2001/XMLSchema#string

Liangping Peng

http://www.w3.org/2001/XMLSchema#string

Michael Linden

http://www.w3.org/2001/XMLSchema#string

Roberto D Polakiewicz

http://www.w3.org/2001/XMLSchema#string

Siegfried Janz

http://www.w3.org/2001/XMLSchema#string

Wan Cheung Cheung

http://www.w3.org/2001/XMLSchema#string

P2860

c-Myc augments gamma irradiation-induced apoptosis by suppressing Bcl-XL

Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas

129-derived strains of mice are deficient in DNA polymerase iota and have normal immunoglobulin hypermutation

Apoptosis triggered by Myc-induced suppression of Bcl-X(L) or Bcl-2 is bypassed during lymphomagenesis

Induction of apoptosis in fibroblasts by c-myc protein

Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells

The MYC protein activates transcription of the alpha-prothymosin gene.

Multiple myeloma and related disorders. Lessons from an animal model.

Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression.

Efficiency alleles of the Pctr1 modifier locus for plasmacytoma susceptibility

P304

1763-1773

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI200420369

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

113

http://www.w3.org/2001/XMLSchema#string

P50

P577

2004-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15199411

http://www.w3.org/2001/XMLSchema#string

P932

420503

http://www.w3.org/2001/XMLSchema#string